Evaluation of Nanotrap® Microbiome Particles, magnetic hydrogel nanoparticles previously validated for capturing viruses and bacteria in environmental water and clinical specimens, for the capture and concentration of arboviruses and Vibrio cholerae from environmental water.

This study presents an enhanced workflow using Nanotrap Microbiome A and Nanotrap Microbiome B Particles for viral enrichment with the NEBNext® Flu A Integrated Indexing Primer Module protocol, leveraging Oxford Nanopore sequencing for rapid whole-genome characterization. By integrating targeted cDNA synthesis and native barcoding, this approach enables same-day sequencing with improved genome coverage, offering a scalable and high-throughput solution for monitoring influenza

This study looks at fecal markers in surface water contaminated with human wastewater and utilizes a magnetic Nanotrap® Particle for capture and concentration of microbes in these samples for fast and reliable detection. This method is compared to a standard filtration method to determine relative sensitivity.

Urine has traditionally been overlooked in viral diagnostics, with most research focusing on respiratory and blood samples. Advances in molecular testing and metagenomic sequencing have revealed that urine contains a diverse array of viral targets, including both eukaryotic viruses and bacteriophages. Despite these findings, current diagnostic methods, such as molecular assays and culture-based techniques, remain limited by low viral titers, inhibitory matrix components, and

Mass spectrometry–based proteomic analysis is a powerful tool for biomarker discovery, but the detection of low-abundance proteins in complex biological samples such as plasma, serum, cerebrospinal fluid (CSF), and urine remains challenging due to high dynamic range and matrix-specific workflow constraints. The presence of abundant proteins, such as albumin, can mask lower-abundance analytes, limiting proteome depth and sensitivity for clinically relevant targets, including c

Tuberculosis (TB) remains a leading global health concern, causing approximately 1.4 million deaths annually.(1) Early and accurate detection of Mycobacterium tuberculosis in complex clinical samples, such as sputum, is critical for effective diagnosis and treatment. Traditional culture methods, while highly specific, are slow and labor-intensive. Molecular approaches such as qPCR and sequencing provide faster results but are often hindered by inefficient mycobacterial recove